Melanotan-1 Complete Guide: Benefits, Dosing, Side Effects & Research

Introduction

Melanotan-1 is the only member of the Melanotan family that reached FDA approval, and it did so for a narrow medical purpose, not for cosmetic tanning. That distinction is the single most important thing to understand before reading anything else about this peptide. Under its drug name afamelanotide, it is approved to help people with a rare disorder tolerate light. It is not a lifestyle product.

This guide covers what Melanotan-1 is, how it works, what it is approved for, how it is dosed in medical use, its side effects, and what the research actually shows. It also addresses the gray-market versions sold as research peptides, which are a different and riskier proposition than the regulated implant. Melanotan-1 is frequently confused with Melanotan-2, a separate and unapproved compound, so part of the job here is keeping those two straight.

At TrimRx, we believe that understanding your options, including which compounds are actually approved and for what, is the first step toward a more manageable health journey. If you are exploring evidence-based metabolic care, our free assessment quiz is a simple place to begin.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is Melanotan-1?

Melanotan-1 is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), engineered to last longer and bind strongly to the melanocortin-1 receptor. Its prescription form is called afamelanotide and is sold under the brand name Scenesse, made by Clinuvel Pharmaceuticals.

Quick Answer: Melanotan-1, known by the drug name afamelanotide, is the only Melanotan compound with FDA approval. It is sold as Scenesse for a rare light-sensitivity disorder.

The molecule is built from the natural alpha-MSH sequence with chemical modifications that make it more stable and longer acting than the body’s own version. When it activates melanocortin-1 receptors on pigment-producing cells, it ramps up production of eumelanin, the brown-black pigment that absorbs and scatters light. Because it works at the receptor level rather than through sun exposure, it can darken skin and add photoprotection without UV. That property is the basis for its one approved use.

It is worth stating plainly that Melanotan-1 and Melanotan-2 are different molecules. Melanotan-1 (afamelanotide) is approved and well characterized. Melanotan-2 is unapproved, broader in its receptor activity, and associated with a different and larger set of side effects. Conflating them leads to bad decisions.

What Is Melanotan-1 Approved For?

The FDA approved afamelanotide in October 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria, a rare inherited disorder. The European Medicines Agency had approved it earlier, in 2014.

Erythropoietic protoporphyria, or EPP, causes a buildup of a molecule called protoporphyrin that makes the skin intensely painful when exposed to light, even short amounts. People with EPP often cannot be outdoors in daylight without severe burning pain. Afamelanotide helps by increasing protective eumelanin, which lets patients tolerate more light exposure with less pain. That is the entire approved indication. It is not approved for cosmetic tanning, for weight management, for sexual function, or for any general anti-aging or wellness purpose.

This narrow approval is easy to miss in online discussion, where Melanotan compounds are often promoted as tanning shortcuts. The regulated drug exists to solve a specific, painful, rare problem.

How Does Melanotan-1 Work?

Melanotan-1 activates the melanocortin-1 receptor (MC1R) on melanocytes, which triggers increased production of eumelanin. More eumelanin means darker skin and greater natural absorption of light, which is what provides photoprotection.

Normally, MC1R activation happens in response to UV-induced signals as part of the tanning process. Melanotan-1 bypasses that pathway by directly stimulating the receptor. The result is increased pigment independent of sun exposure. In EPP, that extra pigment acts as a built-in shield, reducing the phototoxic reactions that protoporphyrin causes. The mechanism is specific to MC1R, which is part of why afamelanotide has a relatively contained side-effect profile compared with Melanotan-2, which hits a wider range of melanocortin receptors.

The effect is gradual. Skin darkening develops over days after an implant and persists while the implant slowly releases the drug. This is a pharmacologic effect on pigment biology, not a quick cosmetic change.

How Is Melanotan-1 Dosed in Medical Use?

The approved form is a 16 mg bioresorbable implant placed under the skin by a trained clinician, typically every 60 days during periods of higher light exposure. The implant slowly dissolves and releases afamelanotide over time.

The implant is inserted subcutaneously, usually above the hip bone, in a quick in-office procedure. Because it dissolves on its own, it does not need to be removed. The 60-day interval reflects how long meaningful drug levels persist. For patients with EPP, treatment is often timed to the months when daylight exposure is greatest. This is a clinician-administered therapy with a defined dose and schedule, which is very different from the variable self-injected dosing seen with gray-market peptides. There is no approved home-injectable version of Melanotan-1.

What Are the Side Effects of Melanotan-1?

The most common side effects of afamelanotide in trials were generally mild and included nausea, headache, fatigue, skin darkening, and reactions at the implant site. Darkening of existing moles and freckles can also occur, which is expected given its mechanism.

In the regulated EPP studies, the safety profile was acceptable for a chronic therapy, which is why it gained approval. Skin pigmentation changes are an intended pharmacologic effect rather than a true adverse event, though patients should have skin and mole monitoring because any agent that affects melanocytes warrants dermatologic follow-up. Implant-site reactions are usually minor. Because the drug increases pigment broadly, dermatologists generally recommend baseline and periodic skin checks during use.

The picture changes sharply with unregulated Melanotan products bought online. Those carry the added risks of unknown purity, incorrect dosing, contamination, and the well-documented problem of unmonitored mole changes. Reports tied to gray-market Melanotan use include new or changing moles and, in some case reports, melanoma concerns, which is exactly why dermatologic supervision matters.

Is Melanotan-1 Used for Tanning?

Not as an approved therapy. Although Melanotan-1 darkens skin, it is not approved for cosmetic tanning, and the tanning peptides sold online are usually Melanotan-2 or unverified material, not the regulated afamelanotide implant.

This is one of the most common points of confusion. People hear “tanning peptide” and assume Melanotan-1 is a safe shortcut to a tan. The reality is that the only legitimate Melanotan-1 product is a prescription implant for a rare disease, administered by a clinician, and the cosmetic tanning market runs on unapproved compounds with no quality control. Using any Melanotan compound for tanning means stepping outside regulated medicine, with all the risks that implies, including unmonitored changes to moles and skin cancer markers. Dermatologists broadly advise against it.

Is Melanotan-1 Used for Weight Loss?

No. Melanotan-1 has no approved or evidence-based role in weight loss, and it should not be confused with the metabolic peptides and GLP-1 drugs used for that purpose. Its mechanism targets skin pigment, not appetite or metabolism.

Some melanocortin receptors elsewhere in the body do influence appetite, which occasionally leads to confusion, but afamelanotide is selective for the MC1R pigment pathway and was never developed or studied as a weight drug. If your goal is weight management, the relevant evidence base is GLP-1 receptor agonists like semaglutide and dual agonists like tirzepatide, which have large randomized trials behind them. Melanotan-1 belongs to a completely different therapeutic area.

How Does Melanotan-1 Compare to Melanotan-2?

Melanotan-1 is approved, MC1R-selective, and used medically for EPP. Melanotan-2 is unapproved, activates a broader set of melanocortin receptors, and is associated with more side effects including nausea, flushing, spontaneous erections, and pigment changes.

The broader receptor activity of Melanotan-2 is why it produces more off-target effects. It hits receptors involved in sexual function and appetite in addition to pigment, which is why it gained an underground reputation as a multi-purpose peptide. That breadth is a liability, not a feature, because it means more ways for things to go wrong. Melanotan-1, by being selective, is more predictable. Neither gray-market version is quality-controlled, but the medical version of Melanotan-1 exists, while there is no approved Melanotan-2 at all. Anyone weighing these should understand they are not interchangeable.

What Does the Research Actually Show?

The strongest research supports afamelanotide for EPP, where randomized trials showed it increased pain-free light exposure and improved quality of life. Outside EPP, the evidence for any benefit is limited or absent.

The clinical trial program that led to approval demonstrated that patients receiving the implant tolerated more daylight with fewer and less severe phototoxic reactions, and reported better quality of life. That is a real, measured benefit in a population with few options. The FDA reviewed this evidence and approved the drug specifically for that use. For tanning, weight loss, or anti-aging, there is no comparable body of controlled human evidence, and promotional claims in those areas are not supported by approval-grade research. The honest summary is that Melanotan-1 is a well-evidenced drug for one rare condition and an unproven gray-market product for everything else.

Key Takeaway: The FDA approved it in October 2019 to reduce painful light reactions in adults with erythropoietic protoporphyria (EPP).

What Is the History of Melanotan-1?

Melanotan-1 began as a research compound at the University of Arizona in the 1980s, where scientists were studying melanocortin analogs as potential photoprotective agents. The original idea was to use the body’s own tanning hormone, alpha-MSH, to build natural sun protection.

Natural alpha-MSH breaks down too quickly to be useful as a drug, so researchers modified the peptide to make it more stable and potent. That modified molecule became Melanotan-1, later named afamelanotide. Development moved from academic research to Clinuvel Pharmaceuticals, which pursued it specifically for light-sensitivity disorders rather than cosmetic tanning. The path to approval took decades. The European Medicines Agency cleared it in 2014, and the FDA followed in 2019. During those same decades, an unrelated underground market grew around both Melanotan-1 and Melanotan-2 sold as injectable tanning agents, completely separate from the regulated development program. Understanding that split history explains why the same name refers to both an approved drug and a gray-market product.

How Long Does Melanotan-1 Last?

In its approved implant form, afamelanotide releases drug over roughly two months, which is why the dosing interval is about every 60 days. The pigment-darkening effect builds over the first several days after insertion and persists while the implant remains active.

The implant is designed to dissolve slowly, providing a steady release rather than a single spike of drug. As the implant bioresorbs, drug levels gradually decline, and the protective pigmentation fades over the weeks that follow. For patients with EPP who need year-round or seasonal protection, this means repeat implants on a schedule set by their clinician. The long duration is part of what makes the implant practical, since it avoids frequent injections. By contrast, gray-market injectable Melanotan has a much shorter duration per dose, which is why underground protocols involve frequent self-injection, adding to the risk and inconsistency of that route.

Who Should Avoid Melanotan-1?

Anyone with a personal or family history of melanoma or numerous atypical moles should approach any melanocortin agent with caution, and the decision belongs to a dermatologist. Because Melanotan-1 stimulates melanocytes, it can darken and potentially change existing moles, which complicates skin cancer surveillance.

Pregnant or breastfeeding individuals were not the studied population and should avoid it absent specific medical guidance. People with significant liver disease also warrant caution, since the LiverTox database notes the importance of monitoring in patients on melanocortin therapy. For the unregulated online versions, the list of people who should avoid them is effectively everyone, because there is no quality control, no dosing standard, and no medical oversight. The approved implant carries clear candidacy criteria built around the EPP indication. Self-sourced Melanotan has none, which is a major part of why dermatology and poison-control bodies have repeatedly warned against it.

What Monitoring Does Melanotan-1 Require?

Regular skin and mole examinations are the core monitoring recommendation for anyone using a melanocortin agent that increases pigmentation. Because the drug can darken existing lesions, a baseline skin check followed by periodic dermatologic review helps catch any concerning changes early.

In the regulated EPP setting, patients receive their implants from trained clinicians and are followed for both the underlying disorder and skin health. That structure provides the monitoring that makes chronic use reasonable. The absence of this monitoring is precisely what makes gray-market use dangerous. Case reports have linked unsupervised Melanotan use to new or changing moles and, in some instances, melanoma diagnoses, where the lack of routine skin checks meant problems went unnoticed. The lesson is straightforward. The value of Melanotan-1 as a medicine is inseparable from the medical supervision that comes with the approved product.

How Does Melanotan-1 Fit Into Legitimate Medicine Today?

Melanotan-1 occupies a small but real place in dermatology as the first approved therapy for a difficult rare disease. It is not a blockbuster drug, and it was never meant to be a consumer product. Its significance is that it gave people with EPP a tool they did not have before.

For the average reader, the practical takeaway is to separate the two things that share this name. There is afamelanotide, a regulated implant for a rare light disorder, used under specialist care. And there is “Melanotan,” a catch-all term for unregulated injectable peptides sold online for tanning, sexual effects, or general experimentation, with no approval and real documented harms. The first is legitimate medicine for a specific population. The second is something dermatologists and regulators consistently warn against. Keeping that line clear is the most useful thing this guide can offer.

What Questions Should You Ask a Clinician About Melanotan-1?

If you have EPP and are considering afamelanotide, the useful questions are practical ones about candidacy, monitoring, and timing. Ask whether your diagnosis fits the approved indication, what skin monitoring schedule the clinician recommends, and how treatment should be timed around your seasonal light exposure.

It also helps to ask about realistic expectations. Afamelanotide reduces the severity and frequency of phototoxic reactions, but it does not cure EPP or make unlimited sun exposure safe. Patients should still use other photoprotection measures. For anyone who came to this topic through tanning or wellness marketing rather than an EPP diagnosis, the most honest question to ask is whether any Melanotan product belongs in your plan at all. In most cases the answer from a dermatologist will be no, with safer and better-studied alternatives available for whatever goal prompted the interest. A good clinician will redirect you toward those rather than a gray-market peptide.

Path Forward with Evidence-based Care

Melanotan-1 is a good example of why the regulatory status of a compound matters as much as its mechanism. The approved version solves a specific, painful problem under medical supervision. The online versions are a different and riskier thing entirely. At TrimRX, our focus is on FDA-regulated and personalized compounded therapies for metabolic health, prescribed and monitored by licensed clinicians. If you came here researching peptides and want to understand which options are actually appropriate for your goals, the free assessment quiz takes only a few minutes, and our team can help you tell legitimate medicine from marketing.

FAQ

Is Melanotan-1 FDA Approved?

Yes, but narrowly. Under the name afamelanotide (brand Scenesse), it was FDA approved in October 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria. It is not approved for tanning or weight loss.

What Is Melanotan-1 Used For?

Its only approved use is reducing painful light reactions in people with erythropoietic protoporphyria, a rare inherited light-sensitivity disorder. It increases protective skin pigment.

How Is Melanotan-1 Given?

As a 16 mg bioresorbable implant inserted under the skin by a trained clinician, usually every 60 days. There is no approved home-injectable form.

Is Melanotan-1 the Same as Melanotan-2?

No. Melanotan-1 (afamelanotide) is approved and selective for the MC1R pigment receptor. Melanotan-2 is unapproved, hits more receptors, and has a broader side-effect profile.

Can Melanotan-1 Be Used for Tanning?

Not as approved medicine. It darkens skin, but the regulated product is only for EPP, and the tanning peptides sold online are usually unapproved Melanotan-2 or unverified material. Dermatologists advise against using any Melanotan compound for tanning.

Does Melanotan-1 Help with Weight Loss?

No. It has no approved or evidence-based weight-loss use. Its mechanism affects skin pigment, not appetite or metabolism. GLP-1 drugs are the evidence-based options for weight management.

Is Buying Melanotan-1 Online Safe?

No. Online Melanotan products are unregulated, of unknown purity, and not the same as the prescription implant. They carry risks including unmonitored mole and skin cancer changes.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.